July 2025 – Page 12

AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition

5 months ago talkbio0Tagged Acquisition, AstraZeneca, baxdrostat, CinCor Pharma, Clinical Trials, Hypertensive disease, treatment-resistant hypertension, Uncontrolled

AstraZeneca; baxdrostat; CinCor Pharma; hypertension; high blood pressure; phase 3 trial; aldosterone synthase inhibitor; $1.3 billion acquisition; clinical trial win; uncontrolled hypertension; treatment-resistant hypertension

Recent Trends in Specialized Support to Accelerate Biotech Success (2025)

5 months ago talkbio0Tagged Advanced therapies, CROs, operational efficiency, Risk Management, strategic partnerships

biotech support; CROs; advanced therapies; funding; risk management; strategic partnerships; operational efficiency

Biotech Layoff Wave Hits Karyopharm, Century, and Pacira in 2025

5 months ago talkbio0Tagged Biopharma, Biotech Layoffs, Karyopharm Therapeutics, Pacira

biotech layoffs; Karyopharm Therapeutics; Century Therapeutics; Pacira; 2025 workforce reductions; biopharma restructuring

EU Lifts Restriction on Valneva’s Chikungunya Vaccine for Older Adults, Recommends Caution

5 months ago talkbio0Tagged Adverse event, chikungunya vaccine, concerns, Elderly (population group), European Medicines Agency, Ixchiq, label extension, Safety, Valneva

Valneva; Chikungunya vaccine; IXCHIQ; European Medicines Agency; older adults; safety concerns; label extension; adverse events

FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy

5 months ago talkbio0Tagged Capricor Therapeutics, Cardiomyopathies, Cell Therapy, Clinical Data, Complete, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3, Rejection, Response process, United States Food and Drug Administration

FDA rejection; Capricor Therapeutics; deramiocel; Duchenne muscular dystrophy; DMD; cell therapy; cardiomyopathy; clinical data; Phase 3 HOPE-3 trial; Complete Response Letter